Is Cannabis Use Treatment Also Indicated for Patients with Low to Moderate Polysubstance Use? by Neumann, Maria et al.
 
 
 
 
 
Dieses Dokument ist eine Zweitveröffentlichung (Verlagsversion) / 
This is a self-archiving document (published version):  
 
 
 
 
 
 
 
 
 
 
Diese Version ist verfügbar / This version is available on:  
https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-706474 
 
 
 
 
 
„Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFGgeförderten) Allianz- bzw. 
Nationallizenz frei zugänglich.“ 
 
This publication is openly accessible with the permission of the copyright owner. The permission is 
granted within a nationwide license, supported by the German Research Foundation (abbr. in German 
DFG). 
www.nationallizenzen.de/ 
 
Maria Neumann, Gerhard Bühringer, Michael Höfler, Hans-Ulrich Wittchen, Eva Hoch 
Is Cannabis Use Treatment Also Indicated for Patients with Low to 
Moderate Polysubstance Use? 
 
Erstveröffentlichung in / First published in: 
European Addiction Research. 2018, 24 (2), S. 79 – 87 [Zugriff am: 19.05.2020]. Karger. ISSN 
1421-9891.  
DOI: https://doi.org/10.1159/000488345  
  
Research Report
Eur Addict Res 2018;24:79–87
Is Cannabis Use Treatment Also 
Indicated for Patients with Low to 
Moderate Polysubstance Use?
Maria Neumann a    Gerhard Bühringer a, c    Michael Höfler a     
Hans-Ulrich Wittchen a, b    Eva Hoch b    
a
 Work Group Addictive Behaviors, Risk Analysis and Risk Management, Technische Universität Dresden, Dresden, 
Germany; b Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany;  
c
 IFT Institut für Therapieforschung, Munich, Germany
Received: August 3, 2017
Accepted: March 12, 2018
Published online: June 14, 2018
Addiction
cRe es ar h
Eva Hoch, Dr. rer. nat.
Clinic of Ludwig-Maximilians-University Munich
Campus City Centre, Nussbaumstrasse 7
DE–80336 Munich (Germany)
E-Mail Eva.Hoch @ med.uni-muenchen.de
© 2018 S. Karger AG, Basel
E-Mail karger@karger.com
www.karger.com/ear
DOI: 10.1159/000488345
Keywords
Cannabis use disorder · Treatment outcome · Primary and 
secondary outcomes · Predictors · Polysubstance use · 
CANDIS
Abstract
Background: Polysubstance use (PSU) is common among 
patients with cannabis use (CU) and is related to more severe 
CU problems. However, it is unclear how PSU predicts CU 
treatment outcomes beyond CU patterns. We examined the 
frequency, amount, and class of additionally used substanc-
es as predictors for primary and secondary outcomes. Meth-
ods: We conducted crude and adjusted regression analy-
ses for PSU variables as predictors of remission, abstinence, 
 reduction, and secondary outcomes in 166 help-seeking 
 patients from a randomized clinical trial of CANDIS, a 
 cognitive behavioral treatment program. Results: Patients 
with recent illegal PSU experienced more difficulties in re-
ducing their CU (B = –1.22, p < 0.001). In contrast, remission 
rates were slightly higher in patients with a wide variety of 
 last-year-PSU (RD = 0.04, p < 0.001). Amphetamine use 
 predicted poorer outcomes regarding CU-related problems 
(B = –4.22, p = 0.019), and the use of opiates, inhalants, and 
dissociative substances predicted poorer physical health 
outcomes (B = –0.62, p = 0.009; B = –0.96, p = 0.039; B = –1.18, 
p = 0.007). Conclusions: CU treatment is also effective for 
patients with moderate PSU. However, treatment effects 
may be enhanced by addressing specific PSU characteristics 
as part of a modularized program. © 2018 S. Karger AG, Basel
Introduction
The number of treatment-seeking patients with prob-
lems related to cannabis use (CU) has been steadily rising 
[1]. Although it has been reported that cannabis is the 
substance associated with the most problems, approxi-
mately 85% of these patients also consume one or more 
other classes of substances. While effective CU treatment 
programs are now available [2–5], the additional use of 
other substances, termed polysubstance use (PSU) ac-
cording to the 10th revision of the International Statistical 
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Classification of Diseases and Related Health Problems 
(ICD-10) [6], may indicate worse responses to treatment, 
particularly with illegal substance use. The roles of sub-
stance class, variety, and frequency of PSU in predicting 
CU treatment effectiveness have not been elucidated.
Cannabis users often also consume alcohol and nico-
tine, and a minority of them uses further illegal substanc-
es [7, 8]. Although there is considerable variation by 
country and region, the most frequent types of PSU 
among more than 70,000 15- to 16-year-old students 
from 22 European countries were a combination of alco-
hol and nicotine (type 1, 73%), followed by the combina-
tion of alcohol, nicotine, and cannabis (type 2, 20%) and 
type 2 plus at least one illegal substance (type 3, 3.5%) [9]. 
There is evidence from longitudinal studies in the gen-
eral population that previous alcohol and illegal sub-
stance use is associated with CU increases or stability [10–
12], as well as the onset of a CU disorder (CUD) in ado-
lescents and young adults [13, 14]. A latent class analysis 
of 1,089 cannabis users from a community sample found 
that other illegal substance use occurred more often in the 
group with cannabis-related problems than in the non-
problematic users [15]. In a sample of 826 cannabis users 
referred for treatment, the highest severity of cannabis 
dependence, comorbid psychopathology, and dysfunc-
tional cannabis cognitions was reported among those 
who additionally used a wide range of other substances; 
these other substances most often included amphet-
amines, and infrequently included tranquilizers and opi-
ates [8]. Therefore, PSU and especially illegal substance 
use is associated with more severe CU-related problems.
Psychosocial interventions have been shown effective 
in the treatment of CUD. A series of recent reviews and 
meta-analyses have demonstrated that cognitive-behav-
ioral therapies (CBT), including elements of motivation-
al enhancement (ME) and problem solving are especially 
effective in reducing the frequency and severity of CU. 
Furthermore, these treatments are also effective for im-
proving secondary outcomes such as psychosocial func-
tioning [2–5, 16, 17]. However, research has not yet de-
termined whether PSU predicts CU treatment outcomes 
beyond the pattern of CU. It has been suggested that pa-
tients with PSU are more difficult to treat [9, 18] and may 
experience fewer benefits from CU treatments.
We examined PSU as a potential predictor (in a non-
causal interpretation, see [19]) of primary (remission, 
 abstinence/reduction) and secondary (reduction of CU 
 related problems, health improvements) outcomes in 
an  established and effective CBT treatment program 
 (CANDIS; acronym for CANnabis DISorders) for ado-
lescents and adults with CUD [2–5, 16, 20, 21]. According 
to the literature, we hypothesize that patients with PSU of 
illegal substances experience lower abstinence rates. 
Whether and how these relations depend on specific PSU 
features, that is, the variety and frequency of specific il-
legal substance classes and whether PSU also relates to 
remission or secondary outcomes has, to our knowledge, 
not been examined before. These questions will be further 
explored. As PSU may indicate generally more heavy sub-
stance use, we also examined CU characteristics such as 
frequency, dose, mode of administration, use environ-
ment, and age of CU onset. We aimed to determine 
whether these factors account for relationships between 
PSU and treatment outcomes. By addressing the com-
plexity of use patterns in the CU population, which often 
involves multiple substance use, we aim to improve treat-
ment effectiveness for patients who request assistance for 
reducing negative impacts of cannabis in their lives.
Methods
Design and Sample
CANDIS is a 10-session program comprising fully manualized 
individual CBT, including ME and problem-solving training [22, 
23]. Two randomized controlled trials (RCTs) have demonstrated 
high efficacy for various treatment outcomes, including achieving 
abstinence, as well as reducing the frequency of CU, the severity of 
cannabis dependence, and the number and severity of cannabis-
related problems [20, 21].
We used data from an RCT conducted from 2007 to 2010 in 11 
German outpatient addiction treatment centers [2–5, 16, 24]. To 
avoid systematic selection bias, all incoming patients with current 
and regular CU were invited to participate in the study.
The inclusion criteria were as follows: (1) ≥16 years of age, (2) 
current and regular CU at least twice per week over the course of 
the past 12 months, (3) motivation to quit or reduce CU, (4) flu-
ency in the German language, (5) written, informed consent con-
cerning study procedures and assessments, as specified by the ap-
proval of the ethics board of Technische Universitaet Dresden 
(EK313122007).
The exclusion criteria were as follows: (1) ICD-10 dependence 
on alcohol or any illicit substance other than cannabis in the previ-
ous 12 months, (2) current use of opiate substitution or sedative-
hypnotic medication, (3) treatment of CU problems within the 
previous 3 months, (4) a lifetime psychotic disorder, (5) current 
severe major depression, (6) current severe panic disorder, (7) 
acute suicidal tendencies, (8) severe learning disability or a perva-
sive developmental disorder, or (9) indications of severe non-can-
nabis-related intoxication [21].
The sample consisted of 166 patients who had completed 
pre-  and post-assessment forms and participated in the treat-
ment,   either as active or as delayed treatment group start-
ing  immediately after being included into the study or with a delay 
of 3 months respectively. Ages at intake ranged from 16 to 64 years 
(M = 27.0), 87% of patients were men, and CU occurred an average 
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of 3.6 days/week. Detailed characteristics of the complete sample 
that entered treatment (n = 279) and descriptions of the methodol-
ogy are provided in other reports [21, 22, 25]. 
Instruments and Measures
Control Variables
CU patterns were measured at the start of treatment, and in-
cluded an ICD-10 last month diagnosis of cannabis dependence 
[6] measured by the Munich-Composite International Diagnostic 
Interview (DIA-X/M-CIDI) [26] as well as age of CU onset (years), 
days of CU within the last month or within the last week (number), 
and frequency of use (assessed using a modified version of the 
Timeline Followback protocol [27]). Additionally, ratings of pref-
erence for strong doses, smoking alone (use environment), smok-
ing a joint, pipe, or (gravity) bong were also assessed on a self-de-
veloped cannabis questionnaire with a numerical scale ranging 
from 0 (“never”) to 3 (“most of the time”).
Predictor Variables
Measures of PSU were based on the DIA-X/M-CIDI [26], and 
included use frequency for 8 substance groups (Table 1) with 2 
modifications; alcohol replaced cannabis, and answers ranged 
from 1 (“less than once/month”) to 8 (“daily or almost daily”) in-
stead of from 1 to 5. Additional measures were daily nicotine use 
and repeated illegal substance use in the last month (yes/no), as 
well as days of alcohol consumption in the last month before treat-
ment start. From this information, 12 different PSU variables were 
calculated (Table 1).
Treatment Outcomes
The primary outcome measures were abstinence/reductions in 
CU and remission, and the secondary outcomes were reductions 
in CU-related problems and improvements in health conditions.
Abstinence was defined as no CU for at least 7 days after treat-
ment, as indicated by both the self-report of abstinence and a neg-
ative urine toxicology test result (Drug-Screen-Card Multi-7 by 
von Minden GmbH, Moers, Germany) for participants with a self-
reported abstinence therapy goal ([28], n = 150). Remission from 
ICD-10-dependence (full and partial) [29] and remission from 
DSM-IV-abuse were defined by a pre-post comparison of a 4 
weeks-diagnosis, as measured by the DIA-X/M-CIDI [26], before 
treatment intake and upon completion of treatment.
Reduction of CU was assessed by a pre-post comparison of CU 
days in the last 4 weeks before treatment start and upon comple-
tion of treatment. Reductions in CU problems were assessed by a 
pre-post comparison of scores on the Cannabis Use Problem Iden-
tification Test (CUPIT), a brief screening instrument with good 
psychometric properties, which identifies CU problems in users of 
all ages [30]. The CUPIT includes an “impaired control” subscale 
with 10 items regarding the amount of use, use patterns, and abil-
Table 1. Indicators of PSU and their definitions
1–8: Previous year use-frequency of:
1 Alcohol, higher doses (i.e., more than 1.5 L of beer,
0.7 L wine, 0.2 L [hard] liqueurs, whiskey etc.)
Monthly average days of use in the previous year, range 1 
(“no co-use”) – 8 (“daily use of specific substance”)
2 Amphetamines (incl. Speed, Ecstasy, Crystal meth) Transformation:
3 Tranquilizers Original scale Transformed interval scale
4 Opiates (incl. Heroin, Methadone) 0: no use in the previous year
1: <1/month
2: approx. 1/month
3: 2–3 times/month
4: 1/week
5: 2/week
6: 3–4/week
7: 5–6/week
8: daily
0: no use in the previous year
0.5 days/month
1
2.5
4
8
14
22
28 days/month
5 Cocaine (incl. Crack, Coca leaves)
6 Dissociatives (incl. Phencyclidines, e.g., “Angel Dust”)
7 Psychedelics (incl. LSD, Mescaline, Psilocybin
mushrooms)
8 Intoxicative inhalants
9 PSU variety in the previous year Number of different substance classes used within the previous year, 
range 0–9 (“use of 9 different substance classes in the previous year”)
10 PSU frequency in the previous year Monthly average of use days of substance class consumed most frequent 
within the previous year, range 0–28 (“daily use of at least one other 
substance within the previous year”)
11 Regular PSU in the previous month Repeated use of illegal substances, nicotine and alcohol in the previous 
month (4 weeks), range 0–3 (“regular co-use of alcohol, nicotine, and/or 
regular co-use of any further illegal substances”)
12 Regular illegal PSU in the previous month Repeated use of illegal substances in the previous month (4 weeks; yes/no)
PSU, polysubstance use; LSD, lysergic acid diethylamide.
D
ow
nl
oa
de
d 
by
: 
S
LU
B
 D
re
sd
en
   
   
   
   
   
   
 
19
4.
95
.1
43
.1
36
 -
 4
/1
6/
20
20
 8
:5
0:
52
 A
M
Neumann/Bühringer/Höfler/Wittchen/
Hoch
Eur Addict Res 2018;24:79–8782
DOI: 10.1159/000488345
ity to control use; it also includes a “problems” scale with 6 items 
regarding the ability to concentrate and maintain daily routines, as 
well as regarding personal interests.
Health improvements included mental and physical health im-
provements, which were measured by pre-post comparisons of 
self-reported health measures, on a scale from 1 (“very good”) to 4 
(“very bad”). Quality-of-life improvements were also assessed and 
were measured using a shortened version of the World Health Or-
ganization Quality of Life Scale [31], which is a widely field-tested, 
cross-culturally comparable assessment instrument for gauging an 
individual’s health perceptions.
Statistical Analyses
Identification of Relevant Control Variables of CU Patterns
Combined backward/forward selection was conducted on all 
CU pattern variables (α for exclusion = 0.05, α for inclusion of a 
preliminarily excluded covariate = 0.01) for the subsequent regres-
sion analysis of a specific outcome. Analyses were conducted sep-
arately for each outcome in order to identify its specific control 
variables. Binary outcome variables were modeled with logistic re-
gression. Dimensional variables were tested for linearity. If linear-
ity was suggested by kdensity analysis or scatter plots, a linear re-
gression model was calculated (model 1). Additionally, a linear 
regression with robust estimates of standard errors (model 2) and 
a robust linear regression, which yields point estimates that are 
robust against outliers, were calculated (model 3) [32]. In cases 
with similar point estimates, model 2 was given preference. Oth-
erwise, model 3 was preferred. Nonlinear variables were modeled 
by gamma regressions (generalized linear model for positively 
skewed outcomes with logarithmic link functions, which allows 
result interpretations as multiplicative relations).
Identification of PSU Predictors
Each treatment outcome was separately regressed for each in-
dicator. Results on abstinence and remission were modeled with 
risk difference regression to account for the few baseline rates and 
occurring empty cells (Tables 2, 3). The outcomes were adjusted 
for by adding their baseline values to account for regression to the 
mean (crude model). Age, sex, and relevant CU control variables 
determined in the previous step were then incorporated into the 
respective regression model (adjusted model).
Results
One hundred thirty-three patients (80%) completed all 
sessions. The remaining 20% participated on average in 5 
sessions (range 1–9). PSU was not related to retention.
PSU Characteristics
In our sample, 93% of all patients had smoked cigarettes 
daily for at least 1 month at any point in their life, and 72% 
had done so in the last month. Additionally, 88% had con-
sumed other substances and/or alcohol in the last year 
(78% if considering higher doses of alcohol; Fig. 1). Among 
the illegal substances, amphetamines were the most fre-Ta
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quently used (30%), followed by cocaine (18%). Repeated 
illegal substance use in the last month before treatment 
initiation was reported by 10.5% of participants. 
Primary Outcomes: Abstinence, Reduction,  
and Remission
CU days in the last week was a significant predictor of 
abstinence (OR 0.84 per day of use; 95% CI 0.76–0.94; p = 
0.002). Cannabis dependence (mean difference; MD  = 
3.2; 95% CI 0.07–6.24, p = 0.045) and days of use in the 
last month (b = 0.72 per day; 95% CI 0.6–0.87, p < 0.001) 
were significant control variables for CU reduction. 
Of the 90 patients who met the diagnosis for last 
month  cannabis dependence at treatment intake, 84% 
achieved at least partial remission (59% full remission). 
Sixty-nine percent of 109 patients achieved remission 
from DSM-IV-abuse. Younger age predicted partial re-
mission (OR 0.9; 95% CI 0.84–0.97, p = 0.007). 
As expected, patients with recent illegal PSU experi-
enced more difficulties in reducing their CU (b = –1.22, 
p < 0.001; Table 2). However, this effected abstinence 
rates only marginally (b = –0.24, p = 0.044, and not sig-
nificant when applying Bonferroni correction). Concern-
ing remission, a positive relation between most indicators 
of PSU and treatment outcomes was found, although the 
estimated risk difference was overall small (Table 3) and 
was not significant in reference to the previous-month-
illegal use.
Secondary Outcomes
Reduction of CU-Related Problems
Improved cannabis-related problems were predicted 
by dependence at baseline (MD  = 6.12; 95% CI 1.55–
10.68, p = 0.01) and impaired control (CUPIT subscale, 
b = 0.46; 95% CI 0.17–0.75, p < 0.001). Use of inhalants 
and  dissociatives predicted improved cannabis-relat-
ed problems in the robust regression model (b = 14.48; 95% 
CI 1.12–27.85, p = 0.034/b = 18.23; 95% CI 10.66–25.81, 
p < 0.001). In contrast, the use of cocaine or amphet-
amines related to less improvements (b = –1.77; 95% CI 
–3.52 to –0.03, p = 0.047/b = –2.51; 95% CI –4.53 to –0.49) 
but only in the active treatment group. Controlling for 
dependence and impaired control at baseline, as well as 
age and gender, relations remain significant for amphet-
Table 3. Risk difference regression analyses on pre-treatment PSU as predictor of remission in (n = 166) patients with cannabis use treatment
PSU indicator Remission ICD-10-dependencea, b Remission DSM-IV-abusea, c
RD (95% CI) p value RD (95% CI) p value
Previous year PSU variety (1–9 substances) 0.04 (0.03 to 0.06) <0.001 0.07 (0.06 to 0.09) <0.001
Previous-year use frequency, ...all (days/month)
...of specific substances (days/month):
0.014 (0.01 to 0.018) <0.001 0.02 (0.01 to 0.02) <0.0011
Alcohol 0.014 (0.01 to 0.018) <0.0011 0.02 (0.01 to 0.02)1 <0.0011
Amphetamines –0.02 (–0.15 to 0.10) 0.735 0.01 (–0.07 to 0.09) 0.771
Tranquilizers –0.31 (–0.35 to –0.29)
atg: 0.54 (0.25 to 0.83)
<0.001
<0.001
0.04 (–0.004 to 0.09)
dtg: 0.88 (0.6 to 1.18)
0.0742
<0.001
Opiates 0.46 (0.28 to 0.63) <0.001 0.57 (0.48 to 0.66) <0.001
Cocaine 0.03 (–0.09 to 0.14)
atg: 0.08 (0.04 to 0.12)
<0.666
<0.001
0.11 (0.09 to 0.14) <0.001
Dissociatives 0.44 (0.28 to 0.62) <0.001 0.72 (0.54 to 0.90) <0.001
Psychedelics 0.20 (–0.29 to 0.69)
atg: 0.39 (0.19 to 0.60)
<0.425
<0.001
0.75 (0.56 to 0.93) <0.001
Inhalants 0.44 (0.28 to 0.62) <0.001 0.73 (0.55 to 0.90) <0.001
Last-month PSU
Regular illegal PSU (yes/no) 0.07 (–0.13 to 0.27)
dtg: 0.2 (0.06 to 0.03)
0.5192
0.006
–0.02 (–0.32 to 0.28) 0.893
Regular PSU (alcohol, nicotine, any illegal
substance: 0–3) 0.06 (–0.4 to 0.15) 0.263 0.03 (–0.09 to 0.15) 0.630
PSU, polysubstance use; atg, active treatment group; dtg, delayed treatment group; a pre-post-comparison of 4-weeks-diagnosis; 
sample too small for adjusted models; b includes partial and full remission; n = 90; c n = 116; 1 not significant in the delayed treatment 
group solely, but in overall sample; 2 only significant in delayed treatment group (dtg).
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amines (b = –2.56; 95% CI –4.46 to –0.65, p = 0.009) and 
dissociatives (b = 9.59; 95% CI 0.69–18.48, p = 0.035) for 
both treatment conditions.
Health Improvements
Pre-treatment CU patterns were not significantly re-
lated to health improvements. However, patients with reg-
ular illegal PSU in the last month before treatment intake 
showed better improvements in mental health over all 
treatment groups (b = 0.39; 95% CI 0.04–0.73, p = 0.021). 
Further, use of opiates, inhalants, and dissociatives 
were related to worse physical health improvements in all 
treatment groups (opiates: –0.31, 95% CI –0.53 to –0.09, 
p = 0.007; Inhalants: b = –0.48; 95% CI –0.92 to –0.03, p = 
0.035; dissociatives: b = –0.58; 95% CI –0.99 to –0.16, p = 
0.007). The use of cocaine was related to better physical 
health improvements, but only in the active treatment 
group (n = 95, b = 0.11; 95% CI 0.05–0.18, p = 0.001). All 
reported results remained significant after controlling for 
age and sex. A preference for high doses of cannabis 
(exp(b) = 0.80; 95% CI 0.66–0.98, p = 0.030), but no PSU 
indicator predicted perceived quality-of-life improve-
ments.
Discussion
We examined PSU indicators as potential predictors 
of primary and secondary CU treatment outcomes in an 
RCT of patients from 11 outpatient treatment centers in 
Germany. Patients with PSU, including a wide variety of 
substances, more often recovered from dependence or 
abuse. In contrast, they showed less improvement in re-
ducing their CU, especially if they had consumed opiates, 
inhalants, and dissociatives in the last year. Experiences 
with these substances were also related to less improve-
ment in physical health, while recent repeated illegal sub-
stance use related to better mental health improvements 
after treatment. These findings were independent of age, 
sex, and CU patterns.
The unexpected finding of a positive relation between 
PSU and remission suggests that patients with low to 
moderate PSU may particularly profit from certain treat-
ment features. For example, problem solving training 
may be especially beneficial for patients that report a wide 
range of substance use and demonstrate more difficulties 
in reducing their CU. 
CU days and ICD-10 dependence in the last month at 
intake were independent predictors of CU and related 
problem improvements. Patients who initially preferred 
high doses of cannabis experienced more quality-of-life 
improvements, which could be interpreted as treatment 
success. High doses of cannabis can be assumed to impair 
normal functioning to a greater extent than lower doses; 
therefore, treatment effects may be more beneficial for 
those using higher doses by re-establishing daily func-
tioning and quality of life.
Overall, the association between PSU and treatment 
outcomes was not significantly affected by CU patterns, 
which supports that PSU does not merely indicate a 
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Fig. 1. Use of specific substance classes, ex-
cept cannabis and tobacco (n = 166), in the 
previous year.
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heavier substance use behavior; rather, there is an inde-
pendent role of PSU related to the prognosis for CU treat-
ment outcomes.
Among the 8 substance classes considered, alcohol 
was used most frequently, followed by amphetamines 
and cocaine. The rare use frequency of the other sub-
stances rather indicates a pattern of experimentation, 
where future repeated use may not be anticipated. This 
pattern is consistent with the typical profile of PSU [8]. 
Nicotine use was the most frequently co-used substance 
but did not directly relate to any outcome. However, its 
role may have been difficult to detect in our sample, due 
to very limited variability for this measure. The high co-
occurrence of tobacco and CU can be explained by the 
habit to smoke both substances in combination, which is 
common in Germany. Different results may be expected 
in countries were cannabis is often smoked without to-
bacco. 
In our sample, the alcohol use frequency was lower 
than that in the general population. However, a substan-
tial amount of patients regularly consumed higher 
amounts of alcohol (Fig. 1). Our results indicate that al-
cohol use is no hindrance for the successful completion 
of the treatment program.
Mixed results have been achieved in regard to illegal 
substances. In general, illegal substance use was related 
to less reduction in CU, but better improvements in 
mental health problems, including remission from 
abuse and dependence. An exception is the most fre-
quently co-used illegal substance class amphetamines. 
Respective patients experienced less improvement of 
cannabis related problems. However, the amphet-
amines class includes a wide variety of substances and 
effects and findings may be largely due to specific sub-
stances such as Crystal and Ecstasy, but not Speed. It is 
hence suggested to further differentiate this substance 
class in future research to better observe possible nega-
tive effects of certain amphetamines in the treatment of 
CU problems. 
Regarding intoxicative inhalants, dissociatives, and 
opiates, there are some noteworthy findings. First, the 
use of these substances predicted treatment outcomes, 
although they were consumed by a very small number of 
patients and at a low frequency (Fig. 1); second, all con-
sumers of these substances with an initial diagnosis of 
abuse or dependence demonstrated at least partial remis-
sion at treatment end. Although the number of observa-
tions was too low for further analyses, the results lead to 
assume that respective clients especially benefit from ef-
fects of the treatment. On the other hand, use of these 
substances was, in contrast to other patterns of PSU, re-
lated to minor physical health improvement. We hy-
pothesize that the use of these substances may have more 
adverse consequences on one’s physical health status 
even at low consumption frequencies. Their use may also 
indicate a different socio-economic status of the users 
[33, 34]. However, given the small sample size, further 
examinations were not possible and results need to be 
interpreted very cautiously. While the strength of the pa-
per was to focus in a detailed manner on substance class-
es, there may still be some inept categorization of sub-
stances. 
Although the PSU distribution in this sample with 
high ecological validity appears to represent the typical 
PSU profile of cannabis users [1, 8, 9, 15], some substanc-
es were so rarely used that the analysis relied on few ob-
servations with little variance. However, significant rela-
tionships with outcomes were observed despite these 
small rates of use.
Variables including frequency and repeated illegal 
PSU as sum indicators are sensitive to the use distribution 
of each individual substance. In this sample, these vari-
ables primarily represented use of amphetamines, co-
caine, and in parts alcohol. A sample with more frequent 
PSU in all substance categories would probably produce 
different results for the sum variables. However, given the 
ecological validity of the sample, the results likely repre-
sent the population of help-seeking cannabis users in out-
patient treatment.
Severe cases such as participants with a use disorder 
for another illegal substance were excluded from partici-
pation and are not represented here. However, our results 
are encouraging that patients with more severe PSU may 
also benefit from a similar treatment, although factors 
such as poorer health must be considered.
Two of our three health improvement measures relied 
on single questions. When replicating the explorative 
findings on these secondary outcomes with directed hy-
potheses, future research should use more sophisticated 
instruments. Measures of primary outcomes were objec-
tive (i.e., the urine toxicology test) and relied on estab-
lished diagnostic instruments (e.g., DIA-X/M-CIDI).
Another strength of our analyses is the consideration 
of different PSU concepts. This feature allows differentia-
tion of crucial PSU profiles and is methodologically im-
portant, since findings also depend on the fit between 
variable formats for predictors and outcome. Further-
more, all of our results included controls for patterns of 
CU, sex, and age as important covariates. The present 
findings are derived from a multicenter study with high 
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methodological quality, a treatment protocol with dem-
onstrated efficacy, and high ecological validity [2–5, 16, 
20, 21].
Conclusions
Patients with CU problems benefit from participation 
in modular treatment combining ME, CBT, and problem 
solving, even, and in some cases in particular, if they ex-
hibit low to moderate PSU. Future research should test 
the robustness of these results and examine more closely 
the predictor-treatment-interaction. It should be tested 
how success variables change for patients who do not re-
ceive treatment (including control groups and self-in-
structed quitting attempts in the general population), as 
well as for patients with more severe PSU.
Overall, our results are encouraging with respect to treat-
ing cannabis users with PSU with this effective  program 
[2–5, 16, 20, 21]. However, the special needs of specific PSU 
characteristics should be considered. For example, patients 
could be offered more intensive and specific support in re-
ducing CU or achieving abstinence and handling physical 
health problems. We suggest considering these special PSU 
characteristics as additional components of a modularized 
program, in order to further improve existing concepts.
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